BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studies
BIGH3 is a potential non-invasive biomarker of MASLD related fibrosis. It may be beneficial for diagnosing significant fibrosis in MASLD patients.
Authors
- Yan Luo (ORCID: https://orcid.org/0000-0002-5271-5126)
- Fen Zhuge
- Jin Yang (ORCID: https://orcid.org/0009-0001-6263-0695)
- Junping Shi (ORCID: https://orcid.org/0000-0001-9434-897X)
- Yu Song (ORCID: https://orcid.org/0000-0002-8835-9071)
- Jianing Kong
- Jing Liu (ORCID: https://orcid.org/0000-0002-3311-0818)
- Zhenjie Zhuang (ORCID: https://orcid.org/0000-0002-3688-1669)
- Yinlan Liu (ORCID: https://orcid.org/0000-0002-3552-9508)
- Huiqin Zhang (ORCID: https://orcid.org/0000-0003-3830-0968)
- Wenjun Yang (ORCID: https://orcid.org/0000-0003-2021-595X)
Institutions
- Zhejiang Chinese Medical University (CN)
- Hangzhou Normal University (CN)
- Affiliated Hospital of Hangzhou Normal University (CN)
- Zhejiang Academy of Medical Sciences (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1186/s12876-025-04275-2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00